Deacetylase inhibition promotes the generation and function of regulatory T cells

Nature Medicine

Volumn 13, Issue 11, 2007, Pages 1299-1307

  Tao, Ran ^a   De Zoeten, Edwin F ^a,b   Özkaynak, Engin ^a,b   Chen, Chunxia ^a   Wang, Liqing ^a   Porrett, Paige M ^b   Li, Bin ^b   Turka, Laurence A ^b   Olson, Eric N ^c   Greene, Mark I ^b   Wells, Andrew D ^a,b   Hancock, Wayne W ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2; RAPAMYCIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3;

ACETYLATION; ALLOGRAFT; ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN; CONTROLLED STUDY; ENZYME INHIBITION; GENE EXPRESSION; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ANIMALS; CELL DIFFERENTIATION; FORKHEAD TRANSCRIPTION FACTORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; LYMPHOCYTE ACTIVATION; MICE; MICE, CONGENIC; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND;

EID: 35948980739     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1652     Document Type: Article

References (50)

1. Lam, A.L., Pazin, D.E. & Sullivan, B.A. Control of gene expression and assembly of chromosomal subdomains by chromatin regulators with antagonistic functions. Chromosoma 114, 242-251 (2005).
2. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299 (2002).
3. McKinsey, T.A. & Olson, E.N. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 20, 206-213 (2004).
4. Matsuzaki, H. et al. Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation. Proc. Natl. Acad. Sci. USA 102, 11278-11283 (2005).
5. Tian, L. et al. Reversible histone acetylation and deacetylation mediate genome-wide, promoter-dependent and locus-specific changes in gene expression during plant development. Genetics 169, 337-345 (2005).
6. Nusinzon, I. & Horvath, C.M. Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci. STKE 2005, re11 (2005).
7. Glozak, M.A., Sengupta, N., Zhang, X. & Seto, E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23 (2005).
8. Gu, W. & Roeder, R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595-606 (1997).
9. Reddy, P. et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. USA 101, 3921-3926 (2004).
10. Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174-17179 (1990).
11. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
12. Brunkow, M.E. et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27, 68-73 (2001).
13. Wu, Y. et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126, 375-387 (2006).
14. Ono, M. et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446, 685-689 (2007).
15. Melgar, S., Karlsson, A. & Michaelsson, E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G1328-G1338 (2005).
16. Shintani, N. et al. Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action. Gen. Pharmacol. 31, 477-481 (1998).
17. Elson, C.O. et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev. 206, 260-276 (2005).
18. Lee, I. et al. Recruitment of Foxp3+ T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J. Exp. Med. 201, 1037-1044 (2005).
19. Hricik, D.E. et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am. J. Transplant. 3, 878-884 (2003).
20. Choi, J.H. et al. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy 35, 89-96 (2005).
21. Moreira, J.M., Scheipers, P. & Sorensen, P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 3, 30 (2003).
22. Bennett, C.L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27, 20-21 (2001).
23. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
24. Fontenot, J.D., Gavin, M.A. & Rudensky, A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4, 330-336 (2003).
25. Khattri, R., Cox, T., Yasayko, S.A. & Ramsdell, F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4, 337-342 (2003).
26. Fisson, S. et al. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 198, 737-746 (2003).
27. Chen, W. et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
28. Liang, S. et al. Conversion of CD4 + CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J. Exp. Med. 201, 127-137 (2005).
29. Almeida, A.R., Zaragoza, B. & Freitas, A.A. Competition controls the rate of transition between the peripheral pools of CD4+CD25- and CD4+CD25+ T cells. Int. Immunol. 18, 1607-1613 (2006).
30. Minucci, S. & Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38-51 (2006).
31. Chen, C., Rowell, E.A., Thomas, R.M., Hancock, W.W. & Wells, A.D. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J. Biol. Chem. 281, 36828-36834 (2006).
32. Li, B. et al. FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. Proc. Natl. Acad. Sci. USA 104, 4571-4576 (2007).
33. Parra, M., Kasler, H., McKinsey, T.A., Olson, E.N. & Verdin, E. Protein kinase D1 phosphorylates HDAC7 and induces its nuclear export after T-cell receptor activation. J. Biol. Chem. 280, 13762-13770 (2005).
34. Dequiedt, F. et al. Phosphorylation of histone deacetylase 7 by protein kinase D mediates T cell receptor-induced Nur77 expression and apoptosis. J. Exp. Med. 201, 793-804 (2005).
35. Zhang, C.L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
36. Glauben, R. et al. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176, 5015-5022 (2006).
37. Wood, K.J. & Sakaguchi, S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3, 199-210 (2003).
38. Waldmann, H., Adams, E., Fairchild, P. & Cobbold, S. Infectious tolerance and the long-term acceptance of transplanted tissue. Immunol. Rev. 212, 301-313 (2006).
39. Hancock, W.W., Buelow, R., Sayegh, M.H. & Turka, L.A. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat. Med. 4, 1392-1396 (1998).
40. Wang, L. et al. Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. J. Immunol. 175, 6311-6318 (2005).
41. Fukuzaki, T., Hancock, W.W., Monaco, A.P. & Maki, T. Indefinite survival of skin allografts in adult thymectomized, antilymphocyte serum-treated mice given bone marrow and thymus grafts of donor origin: tolerance induction by donor bone marrow and thymus. Transplantation 65, 1036-1043 (1998).
42. Wang, L. et al. B7-H3 promotes acute and chronic allograft rejection. Eur. J. Immunol. 35, 428-438 (2005).
43. Lee, I. et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J. Immunol. 171, 6929-6935 (2003).
44. Workman, C.J. & Vignali, D.A. Negative regulation of T cell homeostasis by Lymphocyte Activation Gene-3 (CD223). J. Immunol. 174, 688-695 (2005).
45. Thornton, A.M. & Shevach, E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287-296 (1998).
46. Tao, R. et al. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J. Immunol. 175, 5774-5782 (2005).
47. Suchin, E.J. et al. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J. Immunol. 166, 973-981 (2001).
48. Wysocka, J., Reilly, P.T. & Herr, W. Loss of HCF-1-chromatin association precedes temperature-induced growth arrest of tsBN67 cells. Mol. Cell. Biol. 21, 3820-3829 (2001).
49. Zeng, L. et al. HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. J. Cell Biol. 174, 1059-1069 (2006).
50. Pear, W.S., Nolan, G.P., Scott, M.L. & Baltimore, D. Production of high-titer helper-free retroviruses by transient transfection. Proc. Natl. Acad. Sci. USA 90, 8392-8396 (1993).